BRIEF—Supernus announces positive Phase III data for ADHD drug

Supernus Pharmaceuticals has announced positive top-line results from the Phase III P302 study of SPN-812 in adolescents, for the treatment of attention deficit hyperactivity disorder (ADHD).

At daily doses of 200mg and 400mg, the trial met the primary endpoint of improvement in the symptoms of ADHD. Both active doses were well tolerated.

The firm says it will announce top-line data from the final Phase III trial of SPN-812, study P304 in adolescents, by the end of the first quarter of 2019. It expects to file for approval in the USA in the second half of 2020.